Requirements and study design for the next proton FLASH clinical trials: An international multidisciplinary DELPHI consensus Journal Article
| Authors: | Klaver, Y. L. B.; Hoogeman, M. S.; Lu, Q. R.; Bradley, J. D.; Choi, J. I.; Ferris, M. J.; Grau, C.; Guha, C.; Lin, H.; Lin, L.; Mascia, A. E.; Moerman, A. M.; Poulsen, P. R.; Shi, L. Z.; Singers Sørensen, B.; Tian, S.; Vozenin, M. C.; Willey, C. D.; Zhou, S.; Amos, R. A.; Hawkins, M.; Simone, C. B. 2nd |
| Article Title: | Requirements and study design for the next proton FLASH clinical trials: An international multidisciplinary DELPHI consensus |
| Abstract: | Purpose: The FLASH effect, defined as normal tissue sparing while maintaining tumor control with ultra-high dose-rate irradiation, has been demonstrated preclinically in different tumors and tissues. Although the biological mechanisms are unclear, there is a need for clinical trials investigating the value of proton FLASH irradiation (pFLASH). The purpose of this study was to establish an expert consensus regarding prerequisites, study design, and endpoints for the next clinical trials exploring the clinical potentials of pFLASH. Methods and Materials: Delphi methodology was used to develop a systematic expert consensus. An international expert panel was composed of 21 clinicians, physicists, and biologists, well-balanced in expertise and geography, using predefined inclusion criteria. Statements were scored on a 5-point Likert scale in 2 rounds of online questionnaire voting. The definition of consensus was set a priori. Results: The response rate was 100% in both rounds. Preclinical in vivo demonstration of the FLASH effect in normal tissue while maintaining tumor response was deemed essential before starting a clinical trial in a specific tumor site. The next clinical pFLASH trials are advised to include adult patients only, with a minimal expected overall survival of 1 year for palliative settings or, preferably, oligometastatic disease in the ablative setting. The pFLASH effect should be studied in a single treatment modality setting with toxicity reduction as the primary endpoint. Recommendations were formulated on the use of clinical targets and organs at risk constraints, requirements for evaluation and reporting, and accuracy levels and pretreatment verification of dose rates. No consensus was reached on the use of multiple beams, multiple fractions, and fraction dose. Conclusions: There is a need for additional data regarding the influence of fractionation and multiple beam planning. The results of this study can be used to develop roadmaps to guide future clinical trial design. © 2025 The Authors |
| Keywords: | clinical trial; study design; high dose rate; tumor control; delphi methodology; methods and materials; biological mechanisms; ultra-high; multiple beam; normal tissue sparing |
| Journal Title: | International Journal of Radiation Oncology, Biology, Physics |
| Volume: | 123 |
| Issue: | 1 |
| ISSN: | 0360-3016 |
| Publisher: | Elsevier Inc. |
| Publication status: | Published |
| Date Published: | 2025-09-01 |
| Online Publication Date: | 2025-03-31 |
| Start Page: | 296 |
| End Page: | 305 |
| Language: | English |
| DOI: | 10.1016/j.ijrobp.2025.03.047 |
| PUBMED: | 40174648 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work